A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2011
At a glance
- Drugs ARQ 621 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2011 Planned end date changed from 1 Nov 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 13 Sep 2010 Planned end date changed from 1 Feb 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.